Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 6/20 | 0.41 |
| ▸ | JAK2 | O60674 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412901 | 0.85 | OPRD1 (0.51) | OPRD1OPRK1TACR1CHRM4TSHR | |
| SCHEMBL29529542 | 0.84 | GPR119 (0.45) | TACR1KMT2ATSHRALOX15ATM | |
| SCHEMBL2573823 | 0.84 | STS (0.47) | OPRD1OPRK1TACR1KMT2ATSHR | |
| SCHEMBL4406762 | 0.84 | CYP2D6 (0.47) | OPRD1OPRK1TACR1KMT2ATSHR | |
| SCHEMBL2701636 | 0.84 | GPR119 (0.45) | TACR1KMT2ATSHRALOX15ATM | |
| SCHEMBL31158359 | 0.84 | STS (0.47) | OPRD1OPRK1TACR1KMT2ATSHR | |
| SCHEMBL2782441 | 0.84 | JAK2 (0.48) | OPRD1OPRK1TACR1KMT2ATSHR | |
| SCHEMBL2529921 | 0.83 | CA12 (0.54) | OPRD1OPRK1TACR1CHRM4TSHR | |
| SCHEMBL3249093 | 0.83 | KMT2A (0.63) | TACR1KMT2ATSHRALOX15ATM | |
| SCHEMBL31158311 | 0.83 | KMT2A (0.63) | TACR1KMT2ATSHRALOX15ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1740169-B | Arylmethylamine derivatives for use as tryptase inhibitors | AVENTIS PHARMA INC | 2010-04-21 | — | — | CN | disclosed |
| EP-1296972-B1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-12-23 | — | — | EP | disclosed |
| CN-1740169-A | Arylmethylamine derivatives for use as tryptase inhibitors | AVENTIS PHARMA INC (US) | 2006-03-01 | — | — | CN | disclosed |
| US-6977263-B2 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | disclosed |
| CN-1230431-C | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2005-12-07 | — | — | CN | disclosed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20030187020-A1 | Chemical compounds | AVENTISUB LLC | 2003-10-02 | — | — | US | disclosed |
| CN-1439003-A | Arylmethylamine derivatives useful as tryptase inhibitors | AVENTIS PHARM PROD INC (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1296972-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001090101-A1 | ARYLMETHYLAMINE DERIVATIVES FOR USE AS TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | OPRD1 1304/4885OPRK1 490/4885TACR1 289/4885 |
| US-20030187020-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | OPRD1 1304/4885OPRK1 490/4885TACR1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.